COMMUNIQUÉS West-GlobeNewswire

Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
23/06/2026
Combined company to operate as Serapha Bio and to advance Serapha’s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha’s lead program SERP-01 targets the SERPINA1 E342K (PiZZ [...]
UREVO Mid-Year Sale Brings 2026's Biggest Deal Yet to Amazon and Official Website
23/06/2026
BERLIN, June 23, 2026 (GLOBE NEWSWIRE) -- UREVO today announced its 2026 Mid-Year Sale, its biggest promotion of the year, running across UREVO's international Amazon stores and official website. Consumers can save up [...]
Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market
23/06/2026
- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance [...]
Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors
23/06/2026
A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced-proximity therapeutics. Dr. Houston's deep experience with protein [...]
Soleo Health Named URAC Performance Measurement Pioneer for Second Consecutive Year
23/06/2026
FRISCO, Texas, June 23, 2026 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex specialty pharmacy and infusion services, announced today it is a Specialty Pharmacy Pioneer [...]
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
23/06/2026
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM [...]
Advanced Rehabilitation, LLC Expands iKNOT Curriculum to Address Complex Regional Pain Syndrome & Chronic Upper Extremity Problems
23/06/2026
CHARLOTTE, N.C., June 23, 2026 (GLOBE NEWSWIRE) -- Advanced Rehabilitation, LLC today announced the expansion of its educational platform featuring the integrated Kinetic Neuro-Ortho Training (iKNOT) approach. The [...]
Avalo Therapeutics Appoints Ron Philip to Board of Directors
23/06/2026
WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
ApolloMD Welcomes 2026 Emergency Medicine Administrative Fellows and Opens Applications for Next Class
23/06/2026
ATLANTA, June 23, 2026 (GLOBE NEWSWIRE) -- ApolloMD proudly welcomes Nishant Gogna, DO, and Eun Sung “Kevin” Kim, MD, as the incoming physicians for its Emergency Medicine Administrative Fellowship program. ApolloMD [...]
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
23/06/2026
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra [...]
Plus Therapeutics to Provide Business Update Call on June 30, 2026
23/06/2026
Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans HOUSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc [...]
Cytonus Therapeutics Becomes Axiom Biosciences, Pairing Its Regenerative Medicine Programs With AI-Enabled Drug Design
23/06/2026
New name reflects the company’s growth from a regenerative medicine innovator into a broader therapeutics company, with its clinical-stage cell therapy programs remaining at the core SAN DIEGO, June 23, 2026 (GLOBE [...]
Oryn Therapeutics Advances Next Phase of Orynotide™ Macrocyclic Peptide Platform Development with Expanded Leadership Team and Board Anchored by Accomplished Life Sciences Industry Veterans, Company Builders and Drug Developers
23/06/2026
Novel immune reprogramming oral macrocyclic peptides designed for precise modulation of complex biological networks involved in inflammatory, autoimmune and fibro-inflammatory diseases Company appoints Guy Rosenthal, Ph [...]
CGA.vitaslim Announces Mission to Help 5,000 Adults Combat the "Three Highs" and Reclaim Their Health and Wealth in Hong Kong
23/06/2026
HONG KONG, June 23, 2026 (GLOBE NEWSWIRE) -- CGA.vitaslim, a premier health and wellness consultancy, today announced the launch of a new community-focused initiative aimed at helping 5,000 individuals aged 30 to 60 [...]
Transactions in connection with share buy-back program
23/06/2026
Company announcement no. 22 - 26 23 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
23/06/2026
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution [...]
Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
23/06/2026
ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission Orion Corporation (Orion Pharma) today [...]
argenx to Host Autoimmune Myositis R&D Webinar
23/06/2026
June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a [...]
Communiqué de presse : Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes
23/06/2026
Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes Cenrifki représente une avancée [...]

Pages